Dr. Janssen has coordinated two lines of research over the last several years.
- Strategies to identify immune control and disease remission in chronic viral hepatitisIn this research area, Dr. Janssen investigates which virus and host-related conditions are required for immunological control of viral hepatitis B (HBV) and C (HCV), and in parallel, for sustained response to antiviral therapy. Large-scale multicentre clinical HBV and HCV intervention studies were combined with ancillary fundamental studies using an intensive translational approach. Clinical studies on the natural history and outcome of medical interventions of chronic viral hepatitis were mostly investigator-initiated. In 2001 Dr. Janssen was awarded a ZonMW Clinical Fellowship, in 2004 a ZonMW VIDI grant, and in 2008 European grant (VIRGIL, 6th framework) to unravel the immunological mechanism of disease chronicity and response to antiviral therapy in viral hepatitis B and C. Currently he is the Principal Investigator of the Hepatitis B Research Network (HBRN) funded by the National Institutes of Health (NIH).
- Hypercoagulability and liver diseaseDuring his time at the University of Leiden (1998), Dr. Janssen studied on a national level the etiology of thrombosis of the hepatic vasculature. This was a starting point for European large-scale patient-based cohort studies to elucidate the multifactorial aetiology, the prognostic factors and the efficacy of the various treatment modalities for these life-threatening disorders. In 2001, Dr. Janssen founded the European Network for Vascular Disorders of the Liver (En-Vie), a consortium of expert centres from 9 European countries. He received a grant from the European Community (5th framework) to set up national networks, an on-line common database to federate tissue sample banks.
Activities for these research lines resulted in an extensive scientific network, numerous high impact papers and abstracts that were presented at scientific meetings of the American Association for the Study of Liver Diseases during the past five years (2008-2012).
- Future researchDr. Janssen's track record in research on the immune reactivity and long-term outcome of chronic viral hepatitis is a strong basis for future clinical and translational research at the University Health Network (UHN), which hosts the largest liver clinic in North America (Toronto Western Hospital & Toronto General Hospital).
Dr. Janssen is enhancing UHN's Liver Disease Research Program by establishing his own clinical trial and clinical translational research programs, and obtaining financial support for these endeavors from peer review granting agencies and/or industrial partners. More concretely, he intends to initiate coordination of large scale investigator-initiated clinical research on viral hepatitis, autoimmune liver disease and liver cancer. With the number of liver patients in the Greater Toronto Area and, with the large knowledge and infrastructure for hepatology available at UHN, Dr. Janssen hopes this goal can be achieved within 3 years. He also intends to further unravel at a mechanistic level, the relationship between immune reactivity and the disease progression of various liver diseases, by founding a Liver Lab with combined laboratory space and shared common equipment and facilities for fundamental and translational liver research.
Limited sustained response after stopping nucleos(t)ide analogues in patients with chronic hepatitis B: results from a randomised controlled trial (Toronto STOP study).
Gut. 2019 Aug 28;:
Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials.
Syst Rev. 2019 Aug 19;8(1):207
Clin Gastroenterol Hepatol. 2019 Aug 13;:
Gastroenterol Hepatol (N Y). 2019 Jul;15(7):393-395
Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B.
Hepatology. 2019 Jul 15;:
Clin Gastroenterol Hepatol. 2019 Jun 17;:
Patient-reported outcomes in patients chronic viral hepatitis without cirrhosis: The impact of hepatitis B and C viral replication.
Liver Int. 2019 Jun 07;:
Prevalence and Impact of Hepatitis E Virus Infection Among Persons With Chronic Hepatitis B Living in the US and Canada.
Open Forum Infect Dis. 2019 May;6(5):ofz175
Hepatitis B core-related antigen monitoring during peginterferon alfa treatment for HBeAg-negative chronic hepatitis B.
J Viral Hepat. 2019 May 28;:
Professor, Department of Medicine, University of Toronto
Head, University Health Network Liver Clinic